Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Rad

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
Nature Communications|September 11, 2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeuticallyEnkhtsetseg Munkhbaatar, Michelle Dietzen, Deepti Agrawal, et al.
Cell Genomics|March 23, 2023
<i>In vivo</i> interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolutionAnja Fischer, Robert Lersch, Niklas de Andrade Krätzig, et al.
Cancer Cell|June 23, 2023
An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targetsJoscha Griger, Sebastian A Widholz, Moritz Jesinghaus, et al.
Nature|February 21, 2024
B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4Ali Maisam Afzali, Lucy Nirschl, Christopher Sie, et al.
Cell Stem Cell|April 29, 2021
Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cellsMarkus Breunig, Jessica Merkle, Martin Wagner, et al.
Medcomm|June 10, 2026
The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal AdenocarcinomaJanine Murr, Carolin Schneider, Ningjun Duan, et al.
Nature Cancer|February 5, 2022
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironmentChiara Falcomatà, Stefanie Bärthel, Sebastian A Widholz, et al.
Nature Communications|February 19, 2025
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer developmentAnne T Schneider, Christiane Koppe, Emilie Crouchet, et al.
Nature Communications|December 21, 2018
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4Konstantinos Tzelepis, Etienne De Braekeleer, Demetrios Aspris, et al.
Iscience|October 23, 2023
High RIPK3 expression is associated with a higher risk of early kidney transplant failureAdam Wahida, Christoph Schmaderer, Maike Büttner-Herold, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
Nature Communications|September 11, 2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeuticallyEnkhtsetseg Munkhbaatar, Michelle Dietzen, Deepti Agrawal, et al.
Cell Genomics|March 23, 2023
<i>In vivo</i> interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolutionAnja Fischer, Robert Lersch, Niklas de Andrade Krätzig, et al.
Cancer Cell|June 23, 2023
An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targetsJoscha Griger, Sebastian A Widholz, Moritz Jesinghaus, et al.
Nature|February 21, 2024
B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4Ali Maisam Afzali, Lucy Nirschl, Christopher Sie, et al.
Cell Stem Cell|April 29, 2021
Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cellsMarkus Breunig, Jessica Merkle, Martin Wagner, et al.
Medcomm|June 10, 2026
The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal AdenocarcinomaJanine Murr, Carolin Schneider, Ningjun Duan, et al.
Nature Cancer|February 5, 2022
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironmentChiara Falcomatà, Stefanie Bärthel, Sebastian A Widholz, et al.
Nature Communications|February 19, 2025
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer developmentAnne T Schneider, Christiane Koppe, Emilie Crouchet, et al.
Nature Communications|December 21, 2018
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4Konstantinos Tzelepis, Etienne De Braekeleer, Demetrios Aspris, et al.
Iscience|October 23, 2023
High RIPK3 expression is associated with a higher risk of early kidney transplant failureAdam Wahida, Christoph Schmaderer, Maike Büttner-Herold, et al.
Pageof 21